title: Prospective evaluation of a new anti-ulcer agent, ecabet sodium, for the treatment of Helicobacter pylori infection.
abstract: BACKGROUND
  A new anti-ulcer agent, ecabet sodium, is active against Helicobacter pylori.
  
  
  OBJECTIVE
  To assess the efficacy of ecabet sodium for the eradication of H. pylori in patients with gastroduodenal diseases.
  
  
  METHODS
  In a prospective, randomized and controlled study, patients infected with H. pylori were assigned to one of the following two groups: group LA, who received lansoprazole 30 mg o.d. + amoxycillin 500 mg q.d.s. after meals for 2 weeks, and group LAE, who received lansoprazole 30 mg o.d. + amoxycillin 500 mg q.d.s. + ecabet sodium 1000 mg b.d. after meals for 2 weeks. H. pylori status was determined before and at least 4 weeks after the therapy by rapid urease test, histology and a urea breath test.
  
  
  RESULTS
  Of 101 patients (mean age 53 years, range 17-77 years, M/F: 68/33) enrolled in the study, 97 patients completed the protocol. Four patients were withdrawn because of diarrhoea (three from group LA) and skin rash (one from group LAE). The eradication of H. pylori was achieved in 28/48 (58%) patients in group LA and 38/49 (78%) patients in group LAE. The rate of eradication of H. pylori produced by the LAE treatment was significantly higher than that produced by the LA treatment. Side-effects appeared in two patients (malaise 1, skin rash 1) in group LAE and in seven patients (diarrhoea 6, dizziness 1) in group LA. These side effects disappeared spontaneously with cessation of the treatment.
  
  
  CONCLUSIONS
  Ecabet sodium in combination with lansoprazole and amoxycillin increased the rate of eradication of H. pylori. Ecabet sodium appeared to reduce the incidence of diarrhoea as a side-effect of the dual LA therapy.
authors.affiliation: First Department of Internal Medicine, Tokyo Medical and Dental University School of Medicine, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Ohkusa
authors.forename: I
authors.initials: I
authors.lastname: Takashimizu
authors.forename: K
authors.initials: K
authors.lastname: Fujiki
authors.forename: A
authors.initials: A
authors.lastname: Araki
authors.forename: K
authors.initials: K
authors.lastname: Ariake
authors.forename: K
authors.initials: K
authors.lastname: Shimoi
authors.forename: K
authors.initials: K
authors.lastname: Honda
authors.forename: Y
authors.initials: Y
authors.lastname: Enomoto
authors.forename: T
authors.initials: T
authors.lastname: Sakurazawa
authors.forename: T
authors.initials: T
authors.lastname: Horiuchi
authors.forename: S
authors.initials: S
authors.lastname: Suzuki
authors.forename: K
authors.initials: K
authors.lastname: Ishii
authors.forename: T
authors.initials: T
authors.lastname: Ishikura
mesh_terms: D045784:Abietanes; D000293:Adolescent; D000328:Adult; D000368:Aged; D000897:Anti-Ulcer Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003967:Diarrhea / Q000139:chemically induced / Q000382:microbiology; D004224:Diterpenes / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000382:microbiology; D016480:Helicobacter pylori; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies
chemical_list: D045784:Abietanes; D000897:Anti-Ulcer Agents; D004224:Diterpenes; C061681:ecabet